Literature DB >> 31586276

Cerebral Amyloid Angiopathy, Alzheimer's Disease and MicroRNA: miRNA as Diagnostic Biomarkers and Potential Therapeutic Targets.

J Weldon Furr1, Diego Morales-Scheihing1, Bharti Manwani1, Juneyoung Lee1, Louise D McCullough2.   

Abstract

The protein molecules must fold into unique conformations to acquire functional activity. Misfolding, aggregation, and deposition of proteins in diverse organs, the so-called "protein misfolding disorders (PMDs)", represent the conformational diseases with highly ordered assemblies, including oligomers and fibrils that are linked to neurodegeneration in brain illnesses such as cerebral amyloid angiopathy (CAA) and Alzheimer's disease (AD). Recent studies have revealed several aspects of brain pathology in CAA and AD, but both the classification and underlying mechanisms need to be further refined. MicroRNAs (miRNAs) are critical regulators of gene expression at the post-transcriptional level. Increasing evidence with the advent of RNA sequencing technology suggests possible links between miRNAs and these neurodegenerative disorders. To provide insights on the small RNA-mediated regulatory circuitry and the translational significance of miRNAs in PMDs, this review will discuss the characteristics and mechanisms of the diseases and summarize circulating or tissue-resident miRNAs associated with AD and CAA.

Entities:  

Keywords:  Alzheimer’s disease; Cerebral amyloid angiopathy; Intracerebral hemorrhage; MicroRNA; Protein misfolding

Year:  2019        PMID: 31586276      PMCID: PMC7032931          DOI: 10.1007/s12017-019-08568-0

Source DB:  PubMed          Journal:  Neuromolecular Med        ISSN: 1535-1084            Impact factor:   3.843


  222 in total

Review 1.  Unfolding the role of protein misfolding in neurodegenerative diseases.

Authors:  Claudio Soto
Journal:  Nat Rev Neurosci       Date:  2003-01       Impact factor: 34.870

2.  CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease.

Authors:  Katharina Buerger; Michael Ewers; Tuula Pirttilä; Raymond Zinkowski; Irina Alafuzoff; Stefan J Teipel; John DeBernardis; Daniel Kerkman; Cheryl McCulloch; Hilkka Soininen; Harald Hampel
Journal:  Brain       Date:  2006-09-29       Impact factor: 13.501

3.  Associations between biomarkers and age in the presenilin 1 E280A autosomal dominant Alzheimer disease kindred: a cross-sectional study.

Authors:  Adam S Fleisher; Kewei Chen; Yakeel T Quiroz; Laura J Jakimovich; Madelyn Gutierrez Gomez; Carolyn M Langois; Jessica B S Langbaum; Auttawut Roontiva; Pradeep Thiyyagura; Wendy Lee; Napatkamon Ayutyanont; Liliana Lopez; Sonia Moreno; Claudia Muñoz; Victoria Tirado; Natalia Acosta-Baena; Anne M Fagan; Margarita Giraldo; Gloria Garcia; Matthew J Huentelman; Pierre N Tariot; Francisco Lopera; Eric M Reiman
Journal:  JAMA Neurol       Date:  2015-03       Impact factor: 18.302

4.  Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

Authors:  C A Lemere; J K Blusztajn; H Yamaguchi; T Wisniewski; T C Saido; D J Selkoe
Journal:  Neurobiol Dis       Date:  1996-02       Impact factor: 5.996

5.  MicroRNA-384 regulates both amyloid precursor protein and β-secretase expression and is a potential biomarker for Alzheimer's disease.

Authors:  Chen-Geng Liu; Jin-Ling Wang; Lei Li; Pei-Chang Wang
Journal:  Int J Mol Med       Date:  2014-05-13       Impact factor: 4.101

Review 6.  Current and future implications of basic and translational research on amyloid-β peptide production and removal pathways.

Authors:  C Bohm; F Chen; J Sevalle; S Qamar; R Dodd; Y Li; G Schmitt-Ulms; P E Fraser; P H St George-Hyslop
Journal:  Mol Cell Neurosci       Date:  2015-03-04       Impact factor: 4.314

Review 7.  ALS Clinical Trials Review: 20 Years of Failure. Are We Any Closer to Registering a New Treatment?

Authors:  Dmitry Petrov; Colin Mansfield; Alain Moussy; Olivier Hermine
Journal:  Front Aging Neurosci       Date:  2017-03-22       Impact factor: 5.750

8.  Deregulation of neuronal miRNAs induced by amyloid-β or TAU pathology.

Authors:  Annerieke Sierksma; Ashley Lu; Evgenia Salta; Elke Vanden Eynden; Zsuzsanna Callaerts-Vegh; Rudi D'Hooge; David Blum; Luc Buée; Mark Fiers; Bart De Strooper
Journal:  Mol Neurodegener       Date:  2018-10-12       Impact factor: 14.195

9.  miR-132 regulates the expression of synaptic proteins in APP/PS1 transgenic mice through C1q.

Authors:  Nan Xu; Ang-Di Li; Li-Li Ji; Yao Ye; Zhen-Yu Wang; Lei Tong
Journal:  Eur J Histochem       Date:  2019-05-03       Impact factor: 3.188

10.  MicroRNAs can regulate human APP levels.

Authors:  Neha Patel; David Hoang; Nathan Miller; Sara Ansaloni; Qihong Huang; Jack T Rogers; Jeremy C Lee; Aleister J Saunders
Journal:  Mol Neurodegener       Date:  2008-08-06       Impact factor: 14.195

View more
  2 in total

1.  Epigenetic Regulation of Amyloid-beta Metabolism in Alzheimer's Disease.

Authors:  Chuan He; Zhong-Sheng Huang; Chao-Chao Yu; Hai-Hua Wang; Hua Zhou; Li-Hong Kong
Journal:  Curr Med Sci       Date:  2021-01-11

2.  Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells.

Authors:  Zhifeng Wang; Jingmei Liu; Tao Yang; Qinqin Wang; Rong Liang; Jinliang Tang
Journal:  Mol Cell Biochem       Date:  2022-10-11       Impact factor: 3.842

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.